Chief Medical Officer
Education: MD, PhD with specialization in Oncology.
Background: Lars is a medical doctor and specialist in oncology and holds a Ph.D. from the University of Copenhagen. He has worked with clinical development of new cancer treatments for more than 20 years in companies like Novartis, Genmab, Debiopharm and Topotarget and been Senior Medical Director in Merck Serono and Symphogen.
Other ongoing assignments: None.
Year of commencement of the position: 2023 (as Consultant).
Scandion Oncology shares and warrants
312,500 shares, 234,375 TO2 warrants, 78,125 TO3 warrants and 0 Incentive warrants.